Archive for the ‘River blindness’ category

A Minute with NTD expert: Ellen Agler, Chief Executive Officer of the END Fund

March 4th, 2013

END Fund logo

At the recent “Uniting to Combat NTDs: Translating the London Declaration into Action,” we had a chance to catch up with Ellen Agler, Chief Executive Officer of the END Fund. The END Fund is a private philanthropic fund mobilizing resources for neglected tropical diseases in Africa.

Global Network: What does it take for exposed individuals to fight NTDs?

Ellen Agler: When I was in Mali, I also got a chance to see in addition to the mass drug administration other aspects of the program. There is a huge backlog of trichiasis surgery. Blinding trachoma, if it starts advancing, it is incredibly painful… It feels like sand going over your cornea, and you will go blind if you don’t get this surgery in the advanced stages.

And to see how simple of a surgery it was- that it really only took 10 or 15 minutes. [END Fund] do have this incredible message of about 50 cents per person per year can protect you against these seven diseases that cause disability, cause suffering, cause blindness, and really change the trajectory of your life. And that is a simple message, and I think that we’re all rallying to ensure that we can prevent these diseases, we can treat them in the early stage so that no one has to suffer those diseases.

» Read more: A Minute with NTD expert: Ellen Agler, Chief Executive Officer of the END Fund

A Test For River Blindness

February 28th, 2013

 

A boy helps Samuel Nicol, (age unknown) who suffers from onchocerciasis, walk through the village of Gbonjeima, Sierra Leone. Olivier Asselin, 2012.

A boy helps Samuel Nicol, (age unknown) who suffers from onchocerciasis, walk through the village of
Gbonjeima, Sierra Leone. Olivier Asselin, 2012.

Re-posted from Greg Laden’s Blog on ScienceBlogs

River blindness, also called Onchocerciasis, is the result of the infection of several different eye tissues by the nematode Onchocerca volvulus. The bacterium Wolbachia pipientis lives symbiotically in the gut of the nematode, and escapes the small roundworm to cause an inflammatory response in human tissues, which results in damage to the tissue. These infections can occur in a number of different human tissues causing a variety of effects, but when the eye tissues are involved, the result can be river blindness. It is endemic and widespread in several areas of Africa, as well as more restricted areas in South America and the Middle East.

Treatment of the disease involves killing the bacterium, which in turn kills the host nematode, using various anti-biotics. However, as we have learned over recent decades, widespread use of antibiotics can be less than ideal because this can cause selection for resistant strains so that treatment can become generally ineffective across an affected population. Ideally, there would be a reliable test for river blindness infection that would allow more targeted use of treatments.

A research team at Scripps has just published a paper in PNAS that may lead to such a treatment. The team examined urine samples from people who are known to be infected with the nematode Onchocerca volvulus and its attending Wolbachia pipientis bacterium with those who were not thought to be so infected. A massive laboratory based hunt for differences in the contents of the urine was carried out, and one molecule was identified as unique to the infected humans. This was N-acetyltyramine-O,β-glucuronide, which started out as a neurotransmitter found in the nematodes while they are young, which is then converted to N-acetyltyramine-O,β-glucuronide in the human body and eventually secreted in the urine.

The nematode has a somewhat complex lifecycle in which the very young worms infect various tissues and reproduce there, causing the damage to the tissue via the bacterium’s release. This neurotransmitter seems to be unique, or nearly unique, to these young worms. This is important because the nematode is probably widespread in humans in the endemic areas, but as relatively dormant adults found here and there throughout the body. It is only the young reproducing worms that cause the river blindness. Therefore, N-acetyltyramine-O,β-glucuronide specifically identifies individuals at risk of tissue damage to the eyes.

The test is not yet ready for prime time. There needs to be a field test that can be administered easily in conditions where there are only minimal or no clinical facilities. The test materials have to be reasonably inexpensive and not require special handling such as refrigeration. Ideally, this would consist of a urine test strip as have been developed in the past to test for blood sugar levels or pregnancy.

Another important outcome of this finding is the method itself, which the researchers have dubbed “Metabolome-mining.” (The term “metabolome” refers to the full set of metabolites to be found in a particular organism or tissue, similar to the term “genome” for the full set of genes.)

More information will be available at the Scripps Research Institution web site.

Globisch, D, Moreno, A, Hixon, M, Nunes, A., Denery, J., Specth, S., HYoerauf, A, & Jand, K (2013). Onchocerca volvulus-Neurotransmitter Tyramine is a Biomarker for River Blindness PNAS

Keeping score: Will the new NTD Scorecard keep global action on track?

January 16th, 2013


By Simon Bush,
Director of Neglected Tropical Diseases at Sightsavers. See his recent article in the Huffington Post here.

Today sees the publication of an NTD Scorecard which will bring further transformation to the way global partners, from endemic governments, and pharmaceutical companies to NGOs, are working together to achieve the elimination of this group of debilitating diseases.

Developed by the London Declaration partners and published alongside From Promises to Progress, a new report on NTDs, the Scorecard will help translate the aspirational vision of elimination of ten of the NTDs by 2020 into a reality.

When I first started working on NTDs 13 years ago, I never would have imagined progress like this. Elimination of NTDs such as blinding trachoma and river blindness (onchocerciasis) seemed such a distant goal. How things have changed!  We are now seeing promises turn into action which will make a colossal difference to the lives of over a billion people who are affected by NTDs.

The Scorecard sets out the strategic milestones that are crucial if we’re going to see real progress on these ten NTDs – in terms of raising funds, conducting research and development, and ultimately delivering the right number of treatments, to the right people, in the right communities. It’s all about achieving the scale-up needed. » Read more: Keeping score: Will the new NTD Scorecard keep global action on track?

NTD Success Story: Guatemala Eliminates Onchocerciasis Transmission in Huehuetenango

November 28th, 2012

Another battle in the fight against neglected tropical diseases (NTDs) has been won in Guatemala, where onchocerciaisis transmission has been eliminated in Huehuetenango.

A recent article in the Journal of Parasitology Research evaluated onchocerciasis transmission in the department of Huehuetenango in western Guatemala after 22 rounds of mass drug administration (MDA) over 13 years. In 2007-2008, prevalence of infection was determined to be zero percent through eye examinations of residents, antibody detection in school children and parasite detection in black flies. Following the results of this evaluation, mass treatment was halted in 2009 and post treatment surveillance of parasite prevalence in black flies was conducted from 2009-2011. Infection remained at zero percent, validating that transmission had been eliminated in the area.

Onchocerciasis, also known as river blindness, is caused by the parasite Onchocerca volvulus and is transmitted to humans by the bite of black flies. Infection with the parasite can produce nodules, inflammation, discoloration and itching of the skin, as well as lesions that can lead to blindness. Onchocerciasis is found in 37 countries across the world.

The Onchocerciasis Elimination Program of the Americas, or OEPA, was established in 1992 with the goal of supporting national programs in LAC countries to provide twice yearly MDA of ivermectin to a minimum of 85 percent of the eligible population at risk. The Guatemala Ministry of Public Health, with the assistance from OEPA, began MDA for onchocerciasis in 1996, and since 2002 has reached the targeted coverage of the eligible population through twice-yearly MDA. There were four endemic foci for onchocerciasis in Guatemala. Before this study, transmission in two of the four foci had already been declared eliminated. With this recent evidence of elimination in Huehuetenango and with post treatment surveillance being conducted in the fourth foci, Guatemala is well on its way to request the WHO certification of nation-wide elimination in 2015.